Document b5ZO9E21RVpNjvkNydm1jN5k6

CHEMICAL MANUFACTURERS ASSOCIATION DOCUMENTS RELEVANT TO THE ACTIVITIES OF THE INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC) SUPPLEMENT 7 WORK GROUP MEETINGS IN LYON, FRANCE 10-18 MARCH 1987 t Prepared and collected by Robert J. Moolenaar, Ph.D (CMA Observer) Dow Chemical Company Midland, MI 48640 OLI 4133 I IARC SUPPLEMENT 7 WORK GROUP Lyon, France March 10-18, 1987 Prepared and collected by: Robert J. Moolenaar, Ph.D. April 2, 1987 The attached four documents prepared by XARC will be an integral part of the XARC Supplement 7 report due to become available about January, 1988. 1. General Remarks The "General Remarks" draft describes what was done at the meeting and will become the introduction to Supplement 7. It also includes criteria for using short term test data in the classification of chemicals. It is almost final; there will be a few relatively minor changes prior to publication. 2. Document 6 Document 6 includes the actual classification of about 600 chemicals that will appear in Supplement 7. Compounds showing an "N" before the number in the left-hand column were chemicals with no new human data since publication of the last Supplement. If a date is noted in handwriting, this indicates the date of the Monograph in which the compound was reviewed. In most cases the classification for "N" compounds is based on information in that Monograph (see General Remarks). 3. The Preamble The new Preamble to the Monograph Series, together with the General Remarks, provide the basis for classification. 4. The List of Participants *** **** OLI 4134 I CHEMICAL MANUFACTURERS ASSOCIATION DOCUMENTS RELEVANT TO THE ACTIVITIES OF THE INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC) SUPPLEMENT 7 WORK GROUP MEETINGS IN LYON, FRANCE 10-18 MARCH 1987 Prepared and collected by: Robert J. Moolenaar, Ph.D. (CMA Observer) Dow Chemical Company Midland, MI 48640 OLl 4135 IARC Trip Report 10-18 March 1987 Page 2 Some general impressions by this observer follow: 1. The 1ARC staff and participants at the Work Group meeting were very dedicated to doing the best scientific job possible in arriving at the classifications- Some were concerned with the lack of time available for the task, but all will depart convinced they did the best job they could under the circumstances. 2. The criteria (guidelines) in the Preamble and General Remarks were followed very closely. For each compound, three separate evaluations were made with respect to human evidence, animal evidence, and evidence from other relevant data (primarily short term tests). For each compound, separate evaluations were made for human evidence and animal evidence (Sufficient, Limited, Inadequate, No Data), and these evaluations provided the basis for a tentative overall evaluation (1, 2A, 2B, 3 or 4). A recommendation was made to upgrade the tentative overall evaluation based on results of short term tests (or other relevant data, e.g. metabolism) if supportive mutagenicity data existed. The entire Working Group then integrated the separate assessments (human and animal) with the recommendation of the short term test group, applied their judgment, and came up with an overall classification. In most cases, the overall classifications were arrived at by following the rules for combining levels of evidence spelled out in the Preamble and General Remarks. The recommen dations of the short term test group for upgrading were accepted without invoking exceptional circumstances or overriding based on the group's judgment. Consistency was highly valued. In no case did short term test or other relevant data lower the tentative overall evaluation (this was virtually ruled out). 3. The IARC classifications must be viewed as indicating the strength of evidence for carcinogenicity. In general, it is not a weight of the evidence approach. (a) For human data, there was a search for consistency across studies. In a sense, this is "weighing the evidence." However, negative studies could not outweigh positive studies. (b) The evaluation of animal data included only evidence for carcinogenicity to animals. With one or two possible exceptions, relevance to man was not considered by this group in arriving at a classification. Thus, route of administra tion, relevance of tumor type to man, pharmacokinetics, mechanism, metabolism, and human exposure levels or patterns were not considered. The only requirement was that there be two positive studies (to show that the results could be reproduced) to classify a chemical as having sufficient evidence for carcinogenicity to animals. Relevance to humans OLI 4136 IARC Trip Report 10-18 March 1987 Page 3 was assessed by the entire work group, but it was assumed that animal carcinogens present a carcinogenic risk to man. (c) Short term test evaluations may have taken into account negative studies to a degree (I didn't observe this group), but metabolism information was only used when a known metabolite was carcinogenic. Differences in metabolism across species was not discussed to my knowledge. Short term tests or other relevant data could not lower a classification, only raise it. 4. Categories of chemicals were often lumped together for simplicity, for example chlorophenols or nickel and nickel compounds, and this proved particularly troublesome. It is necessary to read the summaries and probably also the original monographs to really understand how to interpret categories. 5. It was recognized that many manufacturing processes have changed with time, and classifications for these processes may no longer be relevant to the present situation. A case in point is boot and shoe manufacture and repair in which closed systems have replaced earlier open processes. A statement appears in the General Remarks that acknowledges this, but there is no mention of it in the summaries. It will be difficult for manufacturers to communicate this with those not intimately familiar with the Monograph Program. 6. Only published data (including papers in final form accepted for publication) were considered. 7. The participants had much difficulty with Group 4. Only one chemical (caprolactam) made it. Some felt the wording "evidence for lack of carcinogenicity" precluded use of the category. OLI 4137 IARC Trip Report 10-18 March 1987 Page 4 Recommendations 1. It is clear that the best and most recent scientific data must be developed well in advance (at least one year) of a scheduled IARC meeting. I recommend that all interested parties attempt to: (a) Get all important information into published form. (b) Make recommendations on experts to participate in the meeting, especially experts on manufacturing processes and mechanisms of toxicity. (c) Assist in the preparation of early drafts of the Mohographs, particularly sections where industry could make a unique contribution. 2. Although industry observers have traditionally been invited to IARC meetings, I recommend that scientists from private research organizations be included in the IARC Working Groups. For example, a number of scientists from the Chemical Industry Institute of Toxicology (CUT) would lend considerable expertise in areas such as chemical carcinogenicity, genotoxicity and epidemiology. 3. Familiarity with much of the information on a chemical, including how it is produced, used, and regulated, its chemistry, and health effects data, often resides with scientists in industries producing or using the chemical. I believe that these industry scientists should be encouraged to share their information and expertise with IARC staff and appropriate working group participants early in the process of monograph development. 4. The appropriate use of IARC classifications in public policy is critical to U.S. industry and the general public. The Preamble states: "The Monographs represent the first step in carcinogenic risk assessment, which involves examination of all relevant information in order to assess the strength of the available evidence that, under certain conditions of exposure, an agent could alter the incidence of cancer in humans." CMA should consider development of guidance on how IARC classifications should be used in the regulatory process. It is unlikely that IARC terminology and actual classifications will change in the foreseeable future, and the classifications will often be transmitted in the form of lists and tables separate from the Preamble and the detailed reviews. Misunderstandings will be the rule rather than the exception. CMA's efforts will be most fruitful if they concentrate on how IARC efforts are best utilized, and on communicating with local, state and federal officials on the appropriate utilization of the classifications. OLI 4138 GENERAL REMARKS Backoround and dbiective General Remarks 2nd draft, rev, 2a J. <sl * An international group of experts in cancer research met in Lyon in February 1982 to re--evaluate the epidemiological and experii carcinogenicity data, as well as data from snort-term studies on 155 4 chemicals and exposures to complex mixtures that had been evaluated in Volumes 1-29 of the IARC Monographs, for which there were seme data on carcinogenicity in hunans. The background, purpose and overall conclusions of the working Group and the evidence on Which the evaluation for each agent was based were issued as Supplement 4 to the IARC Monographs (IARC, 1982). Ibis volume of the IARC Moncxjraijhs, Supplement 7, is an update of Supplement 4 to the IARC Monoaiarhs and represents the conclusions of two IARC Working Groups - cne whiih met in December 19R6 and another which met in March 1987. Ihe aim of the Working Group that met in December 1*B6 was to sirmarite and bring up to date the findings frero tests for genetic and rlt-ed effects and from studies of ENA. dairege, chrcraoscnal effects and nutation in humans for all ... agents (chemicals, groups of chenicals, industrial processes, occupational exposures and Cultural habits) that had been evaluated in volumes 1-42 of the MonoaidtihB and for which sane data cn carcinogenicity in humans were available. Other data considered OLI 4139 General H&rarks 2nd draft, rev, 2a particularly relevant to evaluations of carcinogenicity were also included. The aim of the Working Group that met in March 1957 was two-fold. Hie first was to surmorire and bring up to date the data on carcinogenicity in humans and in experimental aninals far all ... agents (chemicals, groups of chemicals, industrial processes, occupational exposures and cultural habits) that had been evaluated in Volumes 1-42 of the Monoarabhs and far which sane data on carcinogenicity in burtons were available. The second was to make overall evaluations of carcinogenicity to humans for all 617 agents evaluated in Volumes 1-42 of the Monographs, on the basis of all the available data, as described below. Methods The data an animal and hunan carcinogenicity for each of the agents for vhich information on carcinogenicity in humans was available were reviewed and evaluated before the meeting by mentoers of the Working Group, Who prepared draft stannaries of the findings. During the meeting of the Working Group, these summaries and evaluations were discussed, modified as appropriate and adopted. Overall evaluations of carcinogenicity to humans for these agents were made by the Working Group on the basis of the caubined evidence from hunan carcinogenicity data, animal carcinogenicity data, the conclusions of the December 1986 Working Group on studies on genetic and related effects, and other OLI 4140 General Rsnarks 2nd draft, rev, 2a relevant data judged to be of sufficient importance to affect the making of the overall evaluation. Evaluations of carcinogenicity to humans semetimes were made for a group of hurren exposures, e.g., industrial processes and therapeutic combinations. Under such circumstances, the cargosition of different mixtures, and consequently their biological effects, are likely to vary with settings and conditions. Although the degree of evidence for carcinogenicity has been characterized with all possible specificity, it is difficult to be specific for such variable human exposures, vhich are also likely to change considerably over time, e.g., with the introduction of new processes. The Working Group therefore recognizes that the evaluation of a cauolex situation nay not apply to all constituents or to every coitoination. Other relevant data, including the results of tests for genetic and related effects (see Supplement 6), were used by the Working Group in itaking the overall evaluation of carcinogenicity to humans, of an agent "When cne of the following sets of information was available! (1) the agent produces genetic or related effects in exposed humans (i*e., indicative of OTA or chromosomal damage) and also gives positive results in a range of other types of assays; OR OLI 4141 General Berarks "hid draft, rev. 2a (2) the agent is active in a broad spectrum of assays for genetic and related effects, including those involving manitalian cells, and there is evidence from structure-activity and/or metabolism studies that the agent itself reacts covalently with DMA or is likely to be converted to a reactive form in humans. This information was used in two ways: (1) to classify in Group 2K as a probable human carcinogen, an agent for which there is sufficient evidence of carcinogenicity in experimental animals, vnich would otherwise have been classified in Group 2B as a possible human carcinogen: and (2) to classify in Group 2B, as a possible hucran carcinogen, an agent for vfoidh there is limited evidence of carcinogenicity in experimental animals, wAiich would otherwise have been classified in Group 1. In using the above information, it was recognized that certain known carcinogens are not detected in currently used assays for genetic and related effects. . * Overall evaluations of carcinogenicity to humans for agents for which no data on carcinogenicity in hunens was available were made on the combined evidence frcm animal carcinogenicity data and from other relevant data that fell into one of the two categories described above. OLI 4142 General Rfirroxks 2nd draft, rev. 2a Tne overall evaluation was generally based on the surmary and evaluation in the most recent monograph on that agent. Prior to Volume 29 of the Monographs, the evaluations of sufficient, limited, inadequate and no evidence of carcinogenicity were not used. However, an ad hoc group which was convened in 1978 re-evaluated all chemicals evaluated in Volumes 1-19 of the monographs and listed those for which there was considered to be sufficient evidence of carcinogenicity in experimental animals according to the criteria established at that time. Ml chemicals for which there is sufficient evidence of carcinogenicity in experimental animals wrere re-evaluated by the present group. For agents for which there were no data on carcinogenicity in humans and which were evaluated in Volumes 1-19 of the IARC Monographs, prior to the development of criteria for defining limited and inadequate evidence of carcinogenicity, no formal re-evaluation was node. However, based upon data presented in the surrnaries in these volumes, an atteipt wras naae in conjunction with -the Secretariat to judge whether the available data at that time would have met the present criteria for limited and inadequate evidence. For all these conpounds with no data in humans, the Working Group also examined the data from short-term tests and other relevant biological data in Monographs Volumes 14-41. Only those compounds for which data were limited or sufficient in aniiral studies v*ere considered for recategorization based upon the procedures described above. OLI 4143 General Renarks 2nd draft, rev. 2a When additional published data of significant importance to affect the evaluation of sufficient evidence of carcinogenicity in experimental animals (upgrading to or downgrading froiO were available to the Working Group, new summaries and evaluation of the data in experimental aninels was prepared (see page...), and these were used in making the overall evaluations. The criteria for evaluating the degree of evidence for carcinogenicity in hutrens and in experimental aninels and for making the overall evaluation of carcinogenicity to humans are those described in the Preamble to the Monographs, vhich represents the conclusions of two working groups which met in Septenter/October 1936 and in January 193*7 (see p. ). Results and conclusions Ihe assessments of degrees of evidence for carcinogenicity in humans and in experimental animals, as well as the overall evaluations of carcinogenicity to humans, are given in Table 1. A summary of the conclusions of the December 13*36 Working Group on genetic and related effects is given in Appendix 1. Group 1. The Working Group concluded that the following agents are carcinogenic to humans: Group 2A. The Working Group concluded that the following agents are probably carcinogenic to humans: OLI 4144 General Remarks 2nd draft, rev. 2a Group 2B. The Working Group concluded that the following agents are possibly carcinogenic to humans: Group 3. The Working Group concluded that the following agents are not classifiable as to their carcinogenicity to hunans: Group 4. The Working Group concluded that the following agerrt irr- I probably not carcinogenic to hunans: One of the reason for not having more agents in this category is rv -&J, the criterion used for the selection of agents to be considered in the Mcoographs series; i.e., that there is a suspicion for the carcinogenicity of the agents based on either epideniological or experimental observations. Thereforthe monographs represent a /*v _ '*'**A variety of selected of agents) ^ "rd" positive The epideniological evidence for GleiXiAjiwvLe, diazepam, fluorides (inorganic, in drinking-water) and prednisone was considered for classification as `suggesting lack of carcinogenicity' in hunans. The reasons why it could not be so described are given in the texts of each compound. Two chemicals, ferric oxide and methyl parathicn, were considered to have 'evidence suggesting lack of carcinogenicity' in experimental aninals, but there were insufficient supporting data to allow their classification in Group 4. OLI 4145 NJDITICMAL MUTATIONS The Working Group examined -the available experimental data on chemicals evaluated toy previous Working Groups as "having sufficient evidence of carcinogenicity to experimental animals, but for vhich there were no data on humans. The Working Group confirmed the evaluation of sufficient evidence of carcinogenicity for these 11B chemicals, except in one case (gyrcndtrin) where the evaluation of carcinogenicity using the present criteria was considered to be limited. A new sun-nary of the data on this chemical was prepared. The Working Group also reviewed chemicals for which there were no data on humans, but vmich had previously been evaluated as having limited evidence of carcinogenicity in experimental aninels. Taking into account new published data, four chemicals (acetamide, oera-aminoazdbenzene, griseofulvin, and sodium artho-phenylphenate) were re-evaluated as now having sufficient evidence of carcinogenicity in experimental aninals, and new summaries were prepared for these chemicals. In addition, the working Group re--evaluated the available experimental data as given in the Monographs cm eleven chemicals previously evaluated by IARC Working Groups as having no evidence of carcinogenicity to experimental animals. Using the present criteria for evidence suggesting lack of carcinogenicity as given in the Preantole, two chemicals (caprolactam and methylparathion) were re-evaluated as meeting the criteria to be placed into this category. For the retaining nine chemicals, the evaluation of inadequate evidence was adopted. Sunrraries of the available OLI 4146 data on the two chemicals evaluated as having evidence suggesting lack of carcinogenicity were prepared. OLI 4147 I I&8C aphs- SUBBlDSB.X (iff. jqq dsa< i. inadsguue; l- limited? s. guitiaiflax)* Decree of- evident?* Jflimal Overall fiiSjbatior. A N1 A--f^Z(2-.4xino-9H-pyridoC2.3 bjindole) iffi 1 Acetaldehyde N2 Acetamide N3 Acridine orange N4 Acriflavinium chloride 2 Acrolein KS Acrylamide N6 Acrylic acid 1 j 7=/ ND T ND ND ND ' T ND ND S 5 c i i 7 s HD 2B ;6 ^ n> 3 3 J 23 3 All degree of evidence evaluations and overall evaluation entries are provisional and subject t flange by the Working Group. OLI 4148 I -2 - N7 Acrylic fibres 3 Acrylonitrile N8 Acrylcnitrile-tautadiene-styrene copolymers 77 4 Aetincnycin D ''W * t'ow* 5 Adryamycin N9 AF-2 (2-(2-Furyl)-3-{5-mtro-2-furyl)- acrylamide) / f^ 3 6 Aflatoxins Aflatoxin Aflatoxin Aflatoxin Aflatoxin G2 Aflatoxin N10 Aoaritine ,u 1 t: S 7 Aldrin Nil Allyl chlor ide i I5" N12 Allyl isothiocyanate < ^ <f -i Allyl isovalerate ! */ 4* - 8 Aluminium production N13 Anaranth ' Jo Degree of evidence ftimnn Animal ND HD LS ND ND IL S is Overall evaluation 3 3A 3 2 T3 2B S/ ND *t 3 L for 2 meta- lites 7L ND i 3 ND L 3 ND L 3 $ No ND i 1 3 OLI 4149 I I -3- Degree of evidence ttniwn Anisel Overall evaluation N14 5-Aainoacenafithene SIS 2-Aoiflo&nthraquiraie \9i e \ctn id HD N16 para-Aminoazcbgizene HD N17 ortho-Aminoazotoluene i ct i ND H18 para-Aminobenaoic acid l*h 9 9 4-Aminobiphenyl HD s N19 l-Amino-2-nethylanthraquinone M f 1 HD N20 2-Amino-5- (5-ni tro-2-furyl )-l. 3.4-thiadiazole N21 4-Amino-2-nitrophenol .iin? HD HD N22 2-Amiro-5-ni trothi azole N23 11-Aau.noundecanoic acid ^ ** HD HD 10 Amitrole a Anaesthetics, volatile Diethyl ether t Nitrais oxide Cyclopropane Fluroxene Halothane Methoxyflurane Biflurane Isoflurane D''"J /W/x-- x L I L s s i L S 1 L L S' AO /V1 1 AST> 3 3 :e 2B 3 1 3 2B 3 3 3 J0 s0 t I OLI 4150 12 Analgesic mixtures containing phenacetin Rienacetin N24 Angelicins ?L Angelicin Angelicin UVA 5-Methylangelicin 5-Hethylangelicin + UVA 4,4' -Dimethylangelicir. 4,4'-Dinethylangelicin + UVA 4,5'-Dinethylangelicin 4,5'-Dinethylangelicin UVA 4,4 ,6 Trimethylangelicin 4,4',6-Trimethylangelicin UVA 13 Aniline N25 ortho-Anisidine \0, 2 1> N26 para-Anisidine / i 1 N27 Anthanthrene 1* 2 N28 Anthracene N29 Anthranilie acid 1 1 <? N30 Apholate / ? ly Degree of evidence Hunan Anixal sL L5 Overall eveluaticn 1 M ) HD ) ) HD ) ) HD ) ) HD ) ) ND ) J HD ND HD HD HD ND 1 L I L ND HD I L HD HD L s i L T I I ) ) ) ) ) )3 ) ) \/ ) ) ) > ) J 2B 3 3 J 3 3 OLI 4151 -5 - M31 Aramite 14 Arsenic and arsenic Arsanilie acid Arsenic pentoscide Arsenic sulphide Arsenic triaodde Arsine Calcium arsenate Dimethylarsinic acid Lead arsenate V \ Hethanearscnic acid, disodium salt Methanearscnic acid, monosodium salt Potassium arsenate Potassium arsenite Scdivsn arsenate Sodium arsenite ' Sodium cacodylate IS Asbestos: Actinolite Amssite Anthoehyllite Chrysotile Crocidolite Tresolite 16 Attapulgite ke*I 17 Auramine (technical grade) Manufacture of auramine N32 Aurothioglucose / Y7 7 N33 5-Aaaeytidine frf-L. i Degree of evidence ___________________ Bwan Aniaul ND S SL Overall evaluation 2B / ^/ LL 3 X QQ 51 HD L 3 HD L 3 OLI 4152 -- 6 -- H34 ftcaserine t f fL 18 Azathicprine H3S Aziridine /9 1 f ^ N36 2-<l-Aziridinyl)ethanol 1^7j' K37 Aziridyl benzocuincne ^7 N38 Azobenzene 0 B N39 BenzCa3acridine /f ( 3 N40 BenzCc3acridine N41 BeruCa]anthracene /f^ } c * * * . * *-*v*-^ ** ^ 4 s 1**%/ 19 Benzene ^,/W f ^ 20 Benzidine 21 Benzidine-based dyes Direct Black 38 (technical) Direct Blue 6 (technical) Direct Brown 95 (technical) S W- N42 BenzoCb] fluoranthene / f ^ 3 N43 BenzoCj3 fluoranthene /f f 3 H44 BenzoCk 3 fluoranthene 1 % ~i> Degree of evidoice Boon Aninal HD S L HD L HD L HD L HD L . Overall valuatim 2B / 3 3 3 3 HD I HD L HD s s. sc <> s HD s HS s HD s 3 3 ae 1 / 5& 3* 5A 2B 2B 2B OLI 4153 -.7 - H45 BciroCghi]fluoranthene / f3 * H46 BenxoCa]fluorene i*<0 N47 BenzoCb] fluorene N48 BenzoCc]fluorene i*el N49 BenaoCghi Jperylene NSO BenzoCcIphenanthrene /*: 3 NS1 BenzoCa^pyrene 1 ? ' 3 ij'4 4. i vVf 3K52 Benzo[e]pyrene l ** H53 gars-Benzoquinone dioxime / f ? 2- NS4 Benzoyl peroxide - / N55 Benzyl acetate 1's.Pl N5o Benzyl violet 4B a ? ? Degree of evidence Busan Animal HD I HD 1 HD 1 HD I HD I ND I HD S HD I HD L ./V b HD I L HD S Overall evaluation 3 3 3 3 3 3 JA 3 3 3 3 2B OLI 4154 -a- 22 Beryllium and beryllium confounds xUertrandite ore" / Beryllium acetate Beryllium-aluminium alloy Beryllium carbonate Beryllim diloride Beryllium-copper alloy Beryllium-copper-oobalt alloy Beryllium fluoride Beryllium hydroxide Beryllium-nickel allay Beryllium oxide Beryllium phosphate Beryllium silicate Beryllium sulphate Beryl ore Zinc beryllium silicate 23 Betel-quid and areca-nut chewing Betel quid + tobacco Betel quid without tobacco N57 Bisd-aziridinyDmorpholinophosohine sulphide 1 97 ~ NS8 Bis (2-chloroethyl)ether i f T\ NS9 .V. J, 7l,2-Bis(chlorcniethoxy)ethafte j 7 N60 1.4-Sis (chloromethoxymethyl) benzene 7 25 Bis (chloranethyl) ether and dnlorcoethyl methyl ether (technical) Degree of evidence Humn Aniral L Overall eval^ticn ?/) s L1 I l. SD L 3 ND L 3 X s yv'" .ND L 3 ND L 3 Cs / OLI 4155 -9- N61 Bis (2-<*loro-l-metliyletliyl) ether /I ft 26 Bitumens 27 Bleomycins N62 Blue VPS 28 Bracken fern Ptaquiloside Shikindc acid / f 7r J. -> < *6 N63 Brilliant blue PCF 19 If 29 1,3-Butadiene N64 n-Butyl acrylate 19?'' N65 Butylated hydtoxyanisole (BHA) > % N66 Butylated hydroxytoluene (SOT) /*f ^ N67 Butyl benzyl phthalate !"*? 2- N68 f-Butyrolactene < '7 N69 7-Butyrolactcne 1-7 ' Degree at evidence Humn Animal HD L S L L. XL HD L HD HD ND I HD ND ND ND ND ` ND L I L S 1 S L I S 7 Overall evaluation 3 2G ? 3 J. n 3 3 3 3 JB 3 2B 3 3 25 3 OLI 4156 - 10 - c 30 Cadaivso and f*drni TM ooopounds OrtnritBB acetate Cadmium chloride mu oxide ~' J 7 7 J*- s Cadmium sulphate Cadmium sulphide * N70 Cantharidin 7 L N71 Caprolactam N72 Captan N73 Carbaryl 47 . N74 Carbazole 1 ^ ; ) N75 3-Carbethoxypsoraler. 3-Carbethoxypscralen + UVA 31 Carbon blacks > ,. / i _ 32 Carbm tetrachloride * N76 Carroisine 1^7 T N77 Carrageenan Native Degraded 3* * M78 Catechol Degree of evidence Human Animal Overall valuation Lj 5 ;n . ND ND ND ND ND ) ND ) 1 ' //D X ND L c L ** L TJ- Z $c I rND ND s ND I 3 H 3 3. 3 3 * -0 : c 3 /> 2B 3 OLI 4157 - 11 - Met P n7 ' 33 Cageean asbined dienotherapy^ the j^injiiwii i (lnciinnij ww) Degree of evidsiee awn Aniaal . 4J&1 f ^^*4/ 5 ^0 34 Ciloranbucil 35 cmoraaf^emcol 36 Chlordane/Heptachlor N79 Qilordeccne (Kepcne) illf NSC chlordimefonn /^ (see also N89 - para-chloro-ortho-toluidine - a aetafcolite) e NS1 Chlorinated dibenzodioxins other than TOO 77 37 Chlorinated toluenes (production of) Benzyl chloride y ~1 38 Benzal chloride Benzotrichloride Chlomaphva1 zi^ne (N.N-Bis (2-thloroethyl) -2-naphthylamine) NS2 Qilorobenzilate / f / 2. 39 Qilorodifluoromethane ` Ar\ (COW) C: * tN83 Qilorofluoranethane ^ sS z. 1 X1 ND s ND I ND I I L u S rX s4 ND L X (brX X3 ND L Overall evaluation / / 3G j 2B 3 3 3 O' J l 3 3 oh 3 OLI 4158 41 Qvleroform 42 Qilorophenols (Scupaticral exposures to) Pentachlcrophenol 2,4,5-Trichlorophenol 2,4, e-Ttichlorophenol c 0 ,, , J, H, U W ,i\, j ' ^ wf. c 43 Qilorophenoxy herbicides (occupational exposure to) 2.4-D 2,4.5^T (CPA. N84 4-Ohloro-ortho-pheny1ened i amine /*/ V % N85 4-Chloro-tneta-phenylenedi.amine 11 44 Chloroorene \ > N86 Qiloropropham I 1 < NS7 Qiloroquine 1 7^ N83 Chlorothalonil 1 ^ f 3 N89 para-Chloro-ortho-toluidine t 4?5 N90 2-OU.oro-l. 1.1-tri fluoroethane 1 1 ?L 45 Cholesterol Degree of evidence ftanan Anical xA L z 2 4 Overall evaliatim s0 2Q L X L HD S ND 1 It ND z ND I ND L ND S ND L XX 3G 23 3 3 3 3 2B 3 3 OLI 4159 -13 .V 46 QiraniumTand fciranium compounds Qiroeim 0 Qirrini im carbonyl | i ;i , Cobalt-chromium alloy' FerrochrOBdum -- Qiranium III Qiranite ore Basic chromic sulphate Quranic acetate Qiranic chloride * iv4 . > Chromic oxide Qiranic phosphate Qiranium potassiim sulphate Cironium sulphate Qiranium VI Barium chromate Calcium chrotrate Qiranium trioxide Lead chromate / Lead chromate oxide ( Potassium chrocete Potassium dichromate Sodium chroumte Vk- jU<1 7 J` Sodium dichronate Strontium chrorate 7/' Zinc rfiromate Zinc potassium chromate Zinc yellow K91 Qirysene f't S '> 47 Qirymoidine N92 C.I. Disperse Yellow 3 lf1 3' of evidence Busan Animl Overall evaluatiai J 3 S/ ND L IL ND i 3 4 3 OLI 4160 14 N93 Cinranyl anthranilate 48 Cisplatin N94 Citrinin i6! <fC T&\* 7*2*7/- N95 Citrus Red No. 2 14 7/ 49 Clofibrate 50 Coal gasification 51 Coal-tar pitches 52 Coal-tars 53 Coke production N96 Cooper 8-hvdroxyquincline ifH N97 Coronene 1 k ? 3 N98 Coumarin 1*1 7 54 Creosotes N99 meta-Cresidine M ? 2 NIX para-Cresidine 1 7 ? i- N101 Cycasin / f 7 C Degree of evidence Bunn Am'nnl ND I* r5 ND L ND S J- L " At 5 s S \c ND z ND I ND L LS ND I ND s ND s Overall evaluatim 3 24 3 2B 3 i i i / 3 3 3 : /? 3 2B 2B OLI 4161 I - 15 - 55 Cyclaantes Calcium cyelamte Sodium cydamate Cydohexylamine Dicydchexylamine N102 Cyclochlorotine N103 Cyclcpenta[cd]pyrene 56 Cyclophosphamide D 57 Decarbazine N104 D and C Fed No. 9 58 Oapsone N105 Daunomycin /` 7v 59 EOT DDD (TDE) DDE ( N106 Diacetylaminoazotoluene i 7 J- fN107 N.K`-Diaoetylbenzidine \ N108 Diallate / `i ) H-1 2-N109 2,4-Diaminoanisole of evidence Huenn I Animal L Overall evaluation 3 HD 1 l 3 LHD 3 ss / r5 iND X. L HD s x5 iND HD s LHD ND S sa 3 3 2B J0 3 2B 3 2B OLI 4162 - 16 - NI10 4,4'-0iaminodiphenyl ether ft & ~i-- Nil! l,2-Dianino-4-nitiobenzer>e ft "?2* Nil2 1.4Hftasano-2-rutrbbenzene t % 7 P N113 2,4-0iaminotoluene (see also Toluene diisocyanate) 1*7 ? N114 2,5-Diajninotoluene If 7 ' $> mis Diazepam '</- - jl -i.-ii . . Diazowethane 14 Li ' tU6 Dibenz[a,h]acridine * * $ ^ fiU? Dibenz[a, jjacridine ^ N118 DibenzCa.c]anthracene N119 N120 DibenzCa,h]anthracene / 4 /3 S\ -j( W Tr.*j DibenzCa,j3anthracene / <j / 7 **/Cr N121 7H-DibenzoCc,c]carhi7.T. 1 e 1 rr : J N122 DibenaoCa.eJfluoranthene 1i ?3 N123 DibenzoCh,rst Jpentaphene 1 9 7 3 N124 DibeazoCa, e ]pyrene N125 DiberaoC a, hlpyrene 1*1/3 Degree of evidence ftnn Animl ND S ND z ND I ND s Overall evaluation 2B 3 3 2B ND I JX 3 V ND L 3 ND S 2B ND 5 a ND L ND s A, o < x/q ND L- 3 ND S 2B ND L 3 ND L ND s ND s 3 55 2 1 \\ -v '1 . 7 / - OLI 4163 - 17 - Degree of evidence Hmin Animl Ml 26 Dibcfizo{&,i3pyrene Irf ? ^ MD S N127 DibensoCa, lfereoe l*i ? 7 MD S 61 1,2-Dibrocp-3-chlcgopropane I Ml 28 62 63 Diehloroacetyleie cO.***'*'^ ND ortho-Dichlorobenzene vu*,-^! I "' para-Dichlorotoenzene * r 1 c*'** * -* ^JcTT^piTx x' 3,3'-Dichlorcbenzidine I L X s s Ml 29 trans-1,4-Dichlorofcutene 1^7 7 MD I Ml 30 3,3 ` -Diehlor0-4,4 * -diaminodipheny1 ether If 1 f ND s N131 1,2-Dichloroethane 15 7f MD s 64 Dichlorcmethane ft jJ. * * ' i* N132 2.6-Dichloro-oara-phenylenediamine 1*7 f 2- I ND S L N133 1,2-Dichloropropane / ` 65 1,3-Dichloropropene Ml 34 Dichlorvos M13S Dieofol 66 Dieldrin Ml 36 Diepoxybutane 1 *7 ~?C -.jc/a ) ND L J ND I ND L XL ND s Overall evaluation 2B 2B :g 3 3 JL 3 23 2B 23 3 3 5a 3 3 3 2B H r t I- i * $ J-t * i * i ^V. /o>! ,, I ' C. -f-tY.fi \vl OLI 4164 - IB - Degree of evidence __________________ Ftman Aninal N137 Di-(2-ethylhexyl)adipate & 7_ HD L N138 Di-{2-ethyIhexyl)phthalate 8 2. ND S N139 1,2-Diethylhydrazine 7 *-y 67 Diethyl sulphate N140 Diglycidyl resorcinol ether ^ ^ ND s L HD s N141 Dihydrosafrole 7 6 N142 Dihydroxynethylfuratrizine see Panfuran S) '? o MD ND s X N143 Dimethoxane 7 7 ND L 68 3,3 -Dimethoxybenzidine (orthc-Dianisidine) N144 3.3'-0iaethoxybenzidine-;. 4`-di isocyanate IS ND L N145 para-Dimethylaminoa20ber.aene 7 -3 N146 para-Dinethylaininoazobenzened i azo sodium sulphcnate 7S ND S ND I N147 trans-2[ (Dimethylamino )metnylimino]-5- f^S llj [2-(5-nitr^2-furyl) vinyl ]-l, 3.4-oxadiazole ND N148 3.3* -Dinethylbenzidine (ortho-Tolidine) *7 2. ND 69 N149 Dimethylcarbpmoyl chloride h-J* * ?ri1,1-Diaethylhydrazine -7 if , I ND l s s s Overall evaluation 3 2S 2B SA 2B 2-6 3 3 3 2B 3 3 2B 2A 2B OLI 4165 - 19 - N150 1,2-Oiaethylhydrazine 1 */ N151 1,4-Dimthylphenanthrene $ 70 Dimethyl sulphate N152 1,8-Dinitrcpyrene 8 l/ N1S3 Dimtroscpentamethylenetetrajnine *7 (- 71 1,4-0iaxane N154 2,4`-Oiphenyldianine 7 P N155 Disulfiram 7 C. N156 Dithranol / "7 N157 Dulcin 7 Degree of evidmoe Bunn Aniaal ND S HD I r 5 ND i ND i L ND i ND i ND ND i Overall evaluation 2B 3 3 3 36 3 3 3 3 N153 Endrm ~) kJ N159 Eosin 77 72 N160 EpidUorohydrin , tv u.. 1 .. j U',.. I.'.Tt l-l^oxyethyl-3,4-epoxyeyclahexane 74 N161 3.4-nry-6-oethylcyclohery lmethyl-3,4epoxy-6-thylcyclohe]cane cartoxylate J( K162 cia-9,10-Epor/stearic acid 1C ND ND X ND ND ND i z S L L I 3 3 2 ft 3 3 3 OLI 4166 20 73 Erianite N163 Ethiooaaa.de "7 7 N164 Ethyl acrylate gi N165 Ethylene ^^ 74 75 N166 Ethylene dibramide J, ^ W; --.7,.'-..- Ethyleie oxide f f Ethylene sulphide 7 ( , - -4 76 Ethylene thiourea N167 Ethyl nethanesulphonate 7 'j N16S Ethyl selenac 71 N169 Ethyl tellurac 7d N170 Eugenol N171 Evans blue f 3' 7- F N172 Fast green FCF *7 7 N173 Ferban 7C N174 Fluooeturon S3 i Degree of evidence Busan Animal ND L ND S ND Is l3 ND L Ts ND s ND i ND i ND L ND L Overall evaluation / 3 2B 3 3 ft 3 :$ 2B ' 3 3 3 3 ND L ND I ND 1 3 3 3 OLI 4167 - 21 - N175 Fluoranthene N176 Fluorene ~b 77 ^ujrides (inorganic used in drinking-water Fiverspar Fluosilicic acid Sodium fluoride Sodium monofluorophoephate Sodium eilicofluoride Stannous fluoride 7S 5-Fluorouracil 79 Formaldehyde 2-(2-Fonnylhydxazino)-4-(5-nitro-2furyl)thiazole 7^ ?s Furazolidcne N179 Fusarenon-X ; j> ' i' Degree of evidence Huran Animal HD X ND Z TI Overall evalmtiov 3 3 3 IX ls 3 5 fi ND s 2B ND I ND I 3 3 G N180 Glu-P-1 (2-Amino-6-methyl imidazoC4,5-f]quinoline) N181 Glu-P-2 (AmincdipyridoCl.2-a:3`,2'-djimidazole N182 Glycidaldehyde ~] ND S ND s ND s 2B 2B 2B OLI 4168 N183 Glycidyl oleate ? ^ HI84 Glycidyl stearate 7 H185 Grisecfulvln HI86 Guinea green B 7 ? H187 Gyrcxaitrin - 22 - of evidmce Hi nan Anisal HD 1 HD Z HD 5 HD L HD L - Overall evaluation 3 3 3 ** O H 80 Haematite ->J im *-Underground mining of (with exposures to radon) ' , . - -i 81 Hejechlorobenzene x c T HI 88 Hexachiorcbutadiene 7 `j HD 82 Bexachlorocyclohexane iTechnical grade HCH Lindane '/`-`I--*! 1-, 1-tCH I T H189 HexacMoroethane *7 f HD HI90 HexaAlorcphene 7 ^ HD H191 H192 Hexanethylphosphoraru.de *7 *7 v ( I / i" Of ^^ V*** U'M*/*/ Hycanthroe and its mesylate 7 7 ,, <T -i1f* HD HD 83 Hydralazine X X -L<^ $ L < 1 w 5o 3 fi L I S P1 L S& 3 3 2B 3 3 OLI 4169 84 Hydrazine ra.93 Hydrogen peroxide N194 Hydroquinane "7 7 N195 4-Hydroxyazobenzene ^ N196 8-Hydroxyquinoline ~? 7 N197 Hydroxysenkirkine ~1 C - 23 - Degree of evidence Burn Anisal I5 HD L ND I HD I HD I HD I Overall valuation OB 3 3 3 3 3 4 N198 IndenoC1,2,3-od]pyrene fj HD N199 IQ (2-Amino-3-oethyIiiTU.dazo[4,5-]quinoline 8L HD 85 Iren and steel founding 86 Iran-dextran cosplex X N200 Iron-dextrin cccplex "7J HD N201 Iron sorbitol-citric acid cocplex *7i HD N202 Isatidine i- HD 87 Isoniactinic acid hydrazide H203 Isochosphamide &" | I HD S S (/1 S L I L L L 2B 2B / Or 3 3 3 3 3 OLI 4170 68 N204 Isopropyl alcohol manufacture (strong acid""') _ process) ,,. \ Iscprcpyl alcohol - laopripyl oil* i (. ly ii iift- *1*1 i--* T*ipi^nj-k/fc, Iaosafrole 4 Degree of evidence Hunan Aninal Overall evaluation 5 .... ......___ __ 72 1X J 2 HD L 3 J N205 Jacobine ~1 4 ND I 3 K N206 Kaeapferol (see also bracken fern) c L N207 Lasiocarpine -7<; N208 Laurcyl peroxide <T j" ND 1 ND S .ND I 3 2B 3 OLI 4171 - 25 - Degree of evidence Human 89 Tj--^ and load < * ^i imHt /^-Load acetate ' Lead carbonate \ / Lead chloride \ / load naphthenate \ Lead nitrate \ 11 Lead oxide \ --Lead phosphate 1 -Lead subacetate Lead tetroxide i \ 'w. Tetraethyllead / Tetranethylleady Ledate "3 / T Oy ii. -C 1 90 Leather Boot and shoe manufacture and repair Leather dusts -- ^ leather' goods nanufacture Leather tanning and processing "' T J N209 N210 Methylazoxymethanol and its acetate 7 * l: 1 Light green SF 7 J" ND ND N211 Luteoskyrin 7 L ND Animal $ r Vc /v D A J? S L L Overall valuation aa 3 l >* 2B 3 3 H 91 Magenta (technical grade) Manufacture of magenta N212 Halathicn N213 hteleic hydrazide V -X X rND ND i 3 1 3 3 OLI 4172 -26 N214 ftoJjCnaldehyde <fJ>~ D^ree of evidence Human Aniaal ND I Overall evaluation 3 N215 Maneb 7^ ND 1 3 H216 ffanncmistine 7 O ND L 3 N217 HeA-*-C( 2-Aaino-3-methyl-9H-pyrido[ 2,3-to]- <?L indole) ND S 2B N218 Medphalan 7 ^ N219 MelQ (2-Amino-3,4-dimethylimidamo[4,5-f ]quinoline) S'C ND nd I 1 3 3 N220 Melto (2-Amino-3,8-dimethylimidamo[4,5-f]- ?C quinoxaline) ND I 3 N221 Melamine &l ND I 3 92 Melphalan s$ 93 6-Mercaptcpurine 1I N222 Herphalan 7S' ND S - 94 Methotrexate 1J 95 5-Methoxypsoralen 5-44ethoxyps6ralen (Bergapten) X .----------------- 5 SrMetiwxyp^oralen^ UVA , "* t' ^ 0,,>' w# . . t *4-.1 96 8-Methoxypsoralen + UV^(wa-c:,/ 5' T^S s -9e3^H*3xyp8drala-Hithoat^^VA 1 3 PC> w JA 1 N223 MethoxyAlor ffB - ND X J OLI 4173 - 27 - K224 Methyl acrylate PL K225 2-Methylaziridine 7 S* 97 H226 Methyl braoide . 4 *i J Methyl carbamate 7 96 Methyl chloride N227 1-Methylchrysene % 3 N228 2-Methyldirysene 8 3 N229 3-Methylchrysene 7- N230 4-Methylrfuysene -P 3 N231 5-Methylchrysene 3 N2 32 6-Methylchrysene cP 3 H233 N-Methyl-N.4-dirutrosoaniline 7 2 4r- 99 4,4'-Methylene bis{2-chloraaniline) v. * S*fi v- N234 4,4'W4ethylene bis (N.H-dimethyDbentenamine 100 N235 4,4'-Methylene bis (2-oethylaniline) N * C\ ... r 45- "i A.J, 4,4'-Methylenadianiline SL H236 4,4'-Methylenadiphenyl diisocyanate ?T H237 2-Methylfluoranthene & J Degree of evidence Unan Animl HD I HD S 1b HD I Ii HD i HD L HD L HD L HD S HD L HD L Is HD L Js HD S HD HD HD L Overall evaluation 3 2B 3 3 >5 3 3 3 3 2B 3 3 <24 3 SB 2B 3 3 OLI 4174 - 28 - D^ree of evidence Bumn Animl H238 3-Hethylfluoranthme 3 HD I K239 Methyl iodide HD t H240 Methyl nethacrylate 71 HD I K241 Methyl wthanesulphonate *7 t/ HD S N242 2-Methyl-l-nitroanthraquincne (uncertain ? 2jurity) HD S 101 N243 H-Hethyl-H * -nitro-W-nitrosoquanidine fy&uJ *v s h-J 3-rtethylnitrosamnoprapianaldehyde f }' JS HD HD N244 3-Methylnitroscuninopropicnitrile f HD S N245 4-{Methylnitrosacino)-4-( 3-pyridyl)butanal Fj ' HD I Overall evaluation 3 3 3 2B 2B 2A 3 2B 3 N246 4-(Methylnitrosamino)-l-(3-pyridyl)-lbutanene (HNK) f N247 Methyl parathion N248 1-Methylphenanthrene H249 Methyl red N250 Methyl selenac L N251 Methylthiouracil *7 102 Metronidazole ND s IB HD i LC* HD I HD 1 HD I HD S X' S 3 3 3 3 2B 0G OLI 4175 - 29 - 103 Mineral oils N252 Mirex 14 4 i Siytlj**) r C ~PN253 Mitonyein N254 Modaorylic fibres ^ N2S5 (tanccrotaline L -N256 Manurcn 7^ r/.. *f **-tr*l N257 5-{MDrpholinanethyl)-3-C(5-nitro~ furfurylidene) -amino]-2-oxarolidincne 104 Mustard gas 105 Myleran )(1,4-Batanediol diaethanesulphonate Degree of evidsjoe Bumn Aniaal T ND S sND ND ND SND LND 3ND $L Overall vaUaticr. 3t 2B 2B 3 2B 3 an i i N N258 Nafenopin pp N259 l.S-Naphthalenediaaine . N260 1.5-Naphthalene diisocyanate 7^ 106 1-Naphthylaaine 107 108 2-Nachthylanine * 1-tfaphthylthiourea (ANTU) ND ND ND X- S I s L ND I s r ZB 3 3 3 / i 3 OLI 4176 I -X - 109 x Nickel and nickel coqpounds ^tf55l acetate ^ V\ Nickel ammonium sulphate \ / Nidcel carbonate \ Nickel carbonyl \ Nickel diloride Nickel-gallium alloy Nidcel hydroxide / Nickelocene / Nickel oxide / Nicdcel subsulphide Nidcel sulphate / / Nickel refining __ _ N261 Niridazole ~) "7 N262 Ni thiazide fi K263 5-Nitroacenaphthene ~? <? N264 5-Nitro-ortho-anisidine 2_ N265 9--Nitrcanthracene c^ N266 6-NitrobenzoC]pyrene c V N26? 4-Nitrobiphenyl "7 L/ Degree at evidence Hunan Animal -S 3 Overall valuation t ND $ 2B ND L 3 ND S 2B ND L 3 ND ND 3 ND I 3 ND mz 3 -i(iustBiJ0fl5SrLb 4 usd ;o N268 6-Nitrochrysene '*' vi N269 Nitrofen (technical grade) i? ~> K270 3-Nitrofluoranthme J *4 ND I ND S ND I 3 2B 3 OLI 4177 - 31 - N271 5-Nitro-2-furaldeiiyde aemicarbezcne ") Lj N272 1-C (5-Nitrofurfurylidene )amino]-2-imida20lidincne N273 N-[4-( S-Nitrts-2-furyl)-2-thiazolyl ]acetamide 110 Nitrogen sustard N274 Nitrogen mustard N-oxide N275 2-Nitroprqpane <P 2. N276 i-Nitrcpyrene V/ N277 N'-Nitrosoanabasine &'5~ N278 N' -Nitrosoanatabine ~ N279 N-Nitrosodi-n-butylamine 7 N280 N-Nitroscdiethanolamine *7 K281 N282 N-Nitrosodiethylamine -i ^ T>v^; N-Nitrosodiaethylamine N283 N-Nitrosodifhenylaiaine P 2- N284 para-Nitrosodiphenylanine ^ 1. N285 N-Nitrosodi-n-propylanune "7 N2B6 N-Nitroso-N-ethvlurea Skrd "f.tfA-v' Ti*^s "7 ^ of evidence Baan Animal HD Z HD -S Overal-1 value,tier. 3 ND S 2B LS ND s ND s jh 28 2B ND L 3 ND L 3 ND I 3 ND S 28 ND s 23 ND s JT/4 * ND s ae ; ND L 3 ND I 3 ND s 2B ND s 2 4- OLI 4178 - 32 - N2S7 M-Nitroeofolic acid 7f N288 IWJitrosoguvacine yy M289 N-MitroGOguvacoline : :> N290 N-Ni troschydroxyprol ine 7? N291 N-Nitrosctnethylethylandne ~) ? N292 tWIitroso-M-methylurea IS N293 N-Nitroso-N-methylurethane V N294 N-Nitrosanethylvinylandne 13 N295 IWJitrosomorpnsl ine 7S N296 M'-Nitroscnomi cotine N297 N-Nitrosopiperidine r5 - /> ^* N298 N-Nitroscproline N299 H*-Nitrosopyrrol id 1 ne i N300 N-Nitrososarcosine M301 Nitrovin N302 Nylcn 6 V .t % / z C3 7? Degree of evidnce Human Anisal KD I MD MD HD I MD I ND S MD S MD s MD s MD s ND s MD s ND z MD s MD s MD I MD I Overall valuetic 3 3 3 3 2B m 7b 2B 2B 2S 2B 2B 3 2B 2B 3 3 OLI 4179 0 111 Ochratorin A N303 Oestradiol Bustard 7{ N304 Oil Orange SS N305 Orange 1 N306 Orange G ir 7J~ N307 Oxazepam 112 ^ Vv^,0c Sli'Jr.l. V N308 Oxyphenbutazcne 77 P H309 Panfuran S (Dihydroxymethylfuratrizine) N310 Paxasorbic acid 7c H311 Parathion n N312 Patulin S<- N313 Penicillic acid u N314 Pentachdoroethane k9 N315 Perylene n Degree of evidence Bkaun Anixal Overall evaluation XL NO L 3 3 ND S 2B IND * 3 ND I 3 ND L 3 LS 0A ND ND 3 ND S ND L ND I ND 1 ND L ND L ND I 2B 3 3 3 3 3 3 i>.j* * 0 fms *'' Jy * t t. * <-*<--. *-*1 * - fi CKiJ -V* W-"** t--w jji ? OLI 4180 - 34 - 11316 Petasitenine H317 Rienanthrene Jf 113 thenaxepyridineC 2,6-Diamino-3-{ phenylamo) pyridine] 114 fbenelzine and its sulphate N318 Rwnicarbazide "1 C 115 Ifcenobarbital and its sodium salt N319 Phenoxybenzamine and its hydrochloride j? O 116 Ihenylbutazme N320 aeta-Phenylenediamine N321 para-Phenylenediarane 7 "7 c~ U7 N-Phenyl-2-naphthylamine N322 ortho-Rienylphenol : s sodium ortho phenylphenate 118 Phenytoin N323 Piperonyl butoxide 11324 Polyacrylic acid 7J 119 Polybrooinated biphenyls 120 Polychlorinated biphenyls Degree of evidmee Busan Animal HD L HD Z IS derail evaluation 3 3 2/3 IL HD L zs HD L WE HD i ND i TL HD i ND es Ll HD T HD HD I5 L6 3 3 3 3 3 3 3 a <26 J 3 3 fi OLI 4181 - 35 - Degree of evidence Huhti Animal N325 Itolythlarqprcpene -y Cj 1026 Polyethylene 7 KD ND ND I N327 Folynethylene polyphenyl isocyanate "7 KD ND N328 Polymethyl methacrylate 7 ^ KD I N329 Polypropylene "7 KD I N330 Polystyrene 7^ KD I N331 Polytetxafluaroethylene 7 KD I N332 Polyurethane foams / N333 Polyvinyl acetate 7 `j KD I ND 1 N334 Polyvinyl alcohol 7 ^ ND I N335 Polyvinyl chloride 7 7 ND I N336 Polyvinyl pyrrolldone 7 ^ N337 Pcnceau MX S ND L ND S N338 Pcnceau 3R ND s N339 Pcnceau X ' / 0* ND I N340 Potassium bis (2-hydroryethyl Jdithiocarbamate 7 i- ND L N341 Potassium brooate___ ND S 121 Prednisone J T_ Overall ^rvaluaticr 3 3 3 3 3 3 3 3 3 3 3 3 2B 2B 3 3 2B J OLI 4182 - 36 > 122 N342 Procarfauine and its hydrochloride Csvjfc/***. 2 S /* f Proflavine and its salts ] O N343 Prcnetalol hydrochloride 7 7 N344 1,3-Propane sultcne ? V N345 Prochan ~) i N346 t -Propiolactone 7 V N347 n-Propyl carbamate "7 ^ N348 Propylene 1^ 123 ProRlene oxide ., 124 Propylthiouraci1 N349 Pyrene N350 Pyrido[3,4-c3psoralen PC PyridoC 3,4-c]psoraien Pyrido[3,4-c]psoraler. * UVA 7-+tethylpyrido[3,4-c]psoralen 7-MethylpyridoC3,4-c]psoralen + UVA N351 Pyrimethamine "7 7 of evidence Busan I HD Animal s I HD L HD S HD I HD S HD L HD r I5 I5 XHD Overall evaluaticr 3 3 2B 3 2B 3 -5 % SPr 2a 3 ) HD ) ) ND ) HD ND I HD I L ) ) )3 ) ) 3 OLI 4183 Q N352 Quercetin (see also bracken fern) S N353 para-Qjinone "7 "7 N354 CXiintozene (Pentaehloronirrobenzene) *7 *~f of evidence Busan Animl derail evaluati.cn HD L ND I HD L 3 3 3 R 125 Reserpine N355 Resorcinol 1 "7 N356 Retrorsine *7 t N357 Rhodamine B ~) f N358 Riodaaine 6G f N359 Riddelliine 7L N360 Rifaroicin ^ 126 Rubber industry N361 Rjgulosin ' 1 .. ' ... X ND HD HD ND ND HD 5 ND L i L L L I L J I 3 3 3 3 3 3 3 1 3 S N362 Saccharated iron cscide 7 3 HD L 3 OLI 4184 - 121 m? Sacdiarin Sodium saccharin ortho-Toluene sulphcnajaide Safrole 7^ Scarlet red *7 O Degree of evidmse Bumn Animal Is HD S ND 1 N365 Selenium and selenium compounds *7^* U366 Semicarteride hydrochloride 7 C JDfi7 Seneciphylline 7 C. N368 SenJcirkine > 'j. ND I HD L ND &A/D ND L N369 Sepiolite 7 ND I 12SA Sex hormones O-c ;T> Combined oral contraceptives j fc '-^t\*<-S \Ji~t 12SB Sequential oral contraceptives 128C Other oestrogen-progestin combinations Androgens 129 Testosterone and esters testosterone oenanthate testosterone propionate Oestrogens s 130A Qilorotrianisene Overall valuation St o 2B 3 3 3 3 3 3 - 39 - 130B Conjugated oestrogens piperazine oestxone sulphate sodium equilin sulphate sodium oestrone sulphate 13OC Dienoestrol 130D Diethylstilbostrol and its dipropicnate 130E Ethinyl oestradiol 130F Hexoestrol 13CG Mestranol 130H Oestradiol-17 and esters oestradiol 3-benzoate oestradiol dipropicnate oestradiol-17 valerate polyoestradicl phosphate 1301 Oestriol 130J Oestrone and its benzoate f Progestins 131A Qtloraadinone acetate 131B Dinethistercne 131C Ethynodiol diacetate 1310 17 -Hydrcocyprogestercne caproate Degree of evidence ft,men Aninal L Overall valuation NO 0 A/ 0 /V D L, x L X OLI 4186 wA4 r- 4 w - 40 - of evidence 13 IE 13 IF 131G 131H Lyruestrenol MadrorypLugfeatercng acetate Megestrol acetate Norethisterane and its acetate Buman A/f) I A/0 Aninl X L L 1311 Horethynodrel 13U Margestrel 131K Progesterone Other sex honones 132 Clamiphene citrate /V D Al O T r s J 133 Shale oils Jfew oil shale Spent oil shale Residue of shale oil distillation '1 134 Silica crystalline amorphous 135 Smokeless tobacco products s $ L I s L L s J s X X N370 Sodium diethyldithiocarbamate } ^ 136 Soots ?) 137 Spironolactone ND i sX 5 XL Overall evaluation 3 3 * 3 30 3 i 3 ft 3 1 3 1 3 OLI 4187 w - 41 - S371 Sterigaatocystin ^ N372 Streptoeotocin 1f 138 N373 Styrene S US fcnv. fju- /tl . J-'-s.t i&t-lji # &") r e fStyrene-acrylonitrile copolymers *? ^ N374 Styrene-butadiene copolymers ~~j Cj H375 N376 Styrene oxide ritAt/l i*v ^ Succinic anhydride % <5* ^^ N377 Sudan 1 7 Sudan II N379 Sudan III N380 Sudan brcwn RR 7/ 7 >' 7 3' K381 Sudan red 7B 7 J' 139 Sulfafurazole (Sulphisoxazole) N382 Sulfallate C3 140 Sulfamethoxazole N363 Sunset yellow FCF 7 3" N384 Synphytine 'j Of evidence Bjmnn Animal Overall evaluation KD S 2B HD S ZS xL <26 ND KD 3 KD KD 3 KD S KD L KD L KD L KD I *5/9 3 3 3 3 KD I 3 ND I XT KD S XL KD i 3 3 2B 3 3 KD 1 3 - fr-jicf yian'T- OLI 4188 - 42 - Degree of evidence Bmn Animl * Overall valuation T 141 Talc Talc not cmtaining asbestifonn fibres Talc cmtaining asbestifonn fibres N385 Tannic acid and tannins ? (, N386 Terpene polychlorinates (Strobane ) Lf "2N387 2,2* ,5,5`-Tetratf*lorobenzidine 142 Tetrachlorodibenzo-para-dioxin (TCDD) N388 1,1.1,2-Tetraehloroethane (. 143 1,1,2,2-TetracSiloroethane Tetrachloroethylene Tet rachlorvinphos {E90 Tetrafluoroethylene * N391 Thioacetanide N392 4,4' -Thiodianiline 7V } H393 Thiouracil 1^ g394 Thiourea 1H JE95 Thiran ~K \ i. *r,u. ^ \ 7 X3 J I1 ND L 3 ND HD 1 HD X X HD ND ' L 1 s L L s L ND 3 3 CG 3 3 3 3 ND S 2B ND S 2B ND L 3 ND S ND 1 2B 3 OLI 4189 l v n r 43 145 Tobacco Bering (tobacco moke) 146 Toluene diisocyanate (see also 2, 4--diamino- toluene) , . .*. , 2,4-toluene diisocyanate i .^ 2,6-toluene diisocyanate r j v 147 ortho-Toluidine 0 * 4 S -.A.-y . ^ 'i/* f ^ !.*' Te-fi/ --** ** 11396 Ttacaphene (Polychlorinated casphenes) *7^ 14S Treosulphan N397 Trichlorfcn 3 r <S9 1,1,1-Triehloroethane 1,1,2-Ttichloroethane 7^ 7^ 149 H400 ^' 4 * Trichloroethylene * M ' ' -1 - i .) Trichlorotriethylamine hydrochloride 7 J N401 Tj-Ttichothecene 3 N402 Triethylene glyool diglycidyl ether 7 N403 2,4,5-Trimethylaniline g 2- 11404 2,4,6-Trinethylaniline fc"' 2- 150 4,5',8-Trimethylpsoralen 4,5*, 8-Trinethylpooralen 4,5',8-Trinethylpaoralen + UVA of evidence Busan 5 Aninal 5* A/0 s Overall valuation / sJ. HD s 5 /V o HD i HD i HD L JL HD i HD i HD L HD L HD I 1j 2B / 3 3 3 3 3 3 3 3 3 V OLX 4190 1 - 44 - Degree of evidence Bran Anisal H405 Ttipteiylene f3 HD Z 151 Trig (aziridinyl) -para-taenzoquincoe ^ ^ / (Ttii^o) HLefJ z L H406 Tris(l-aziridinyl)phosphine oxide 152 N407 Trisd-aziridinyDphosphine sulphide ClTuotepa) Sr TjTV* " 2,4,6-Tris(l-axiridinyl)--triazine '7J'' N406 1,2,3-Tris (chloremethoxy) propane 7 7 05 TTis(2,3-dibroropropyl)phosphate K409 Tris(2-methyl-l-a2iridinyl)phosphine oxide N410 Trp-P-1 [3-Amino-1,4-dimethyl-5H-pyrido- J [4,3-*]indole) N411 Trp-P-2 [3-Amino-l-n>ethyl-5H-pyrido[4,3-b]indole) g) H412 Trypan blue ~) y HD r HD HD X HD HD HD ND i 3 L L S I s s s Overall evaluaticn 3 3 3 5 A? 3 3 JA 3 2B 2B 2B 0 154 H413 Uracil njstard SirJ W 7-v/r Urethane "7 </ X HD s "& 23 OLI 4191  V 155 Vinblastine sulphate 156 Vinoistine sulphate N414 Vinyl acetate fC N415 157 Vinyl brosu.de \J(-, Vinyl chloride o, ^% , Zt-wwi , 'hi+t* N416 Vinyl chloride-vinyl acetate copolymers N417 4-Vinylcyclchexene r 158 Vinyl fluoride Vinylidene chloride N419 Vinylidene chloride-vinyl chloride copolymers N420 Vinylidene fluoride N421 N-Vinyl-2-pyrrolidine W 159 Wollastaiite of evidence Animal Overall evaluation Jl r Vo ND a ND ND ND X ND ND ND T X i s _c I L Nd L ND 1 ND 3 3 3 m 24 I 3 3 3 3 3 3 2 L3 OLI 4192 160 w.<o_ o-- d Carpentry and joinery___----- Furniture and cabinet asking -- Tnumber and saw Bill industries Pulp and paper sanufacture 46 Degree of evidaice Hunan Aninal ______ _-> L * I j. &D X A> D tv D Overall evaluation 2 <3 J 3 3 X 13422 2.4-Xylidine and its hydrochloride 13423 2,5-XyLidine and its hydrochloride Y 13424 Yellcw AB N42S Yellow OB 2 13426 Zearalenone 13427 Zectran H428 Zineb 13429 Ziraa t f C k\0 , s C *";/ W 0 ( //* t ( ** cV\` <. ('*' ^ HD I HD 1 3 3 ND I ND 3 -*i ND L ND L ND I ND r- Ls LI S OLI 4193 3 3 3 J3 2 /a a i